THERANEXUS is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Thanks to its knowledge of neuron and glial cell interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of drug candidates in clinical-phase testing. The company’s combined drug repurposing… Show more THERANEXUS is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Thanks to its knowledge of neuron and glial cell interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of drug candidates in clinical-phase testing. The company’s combined drug repurposing strategy based on a solid commercial footing and a capability to rapidly demonstrate its clinical value, enables it to produce different high-value-added proprietary drug candidates, significantly reduce development time and costs, and considerably increase the chance of its drugs reaching the market. Accordingly, THERANEXUS is well-positioned in several indications, including for Parkinson’s and Batten disease, for which there is currently no treatment available. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX). Show less

Portfolio Strategy, Commercial and Market Access Development, Organization, Partnering and Investment advisory (Completion of fundraising plan) to Biotechs / Pharma / Nutraceuticals.Pre-acquisition due diligence with Private Equity / Venture and Seed Capital firms in Health.

TargEDys is a clinical and commercial stage biotech based in France. TargEDys has been in the list of 20 European biotechs to follow since 2020 (Labiotech.eu). TargEDys translates its unique understanding of the gut-brain axis to develop and manufacture nutritional and therapeutic solutions to control metabolic diseases. As a European pioneer in microbiome research, the company aims to be at the forefront of safe and effective weight management to improve the health and life quality of many… Show more TargEDys is a clinical and commercial stage biotech based in France. TargEDys has been in the list of 20 European biotechs to follow since 2020 (Labiotech.eu). TargEDys translates its unique understanding of the gut-brain axis to develop and manufacture nutritional and therapeutic solutions to control metabolic diseases. As a European pioneer in microbiome research, the company aims to be at the forefront of safe and effective weight management to improve the health and life quality of many over and underweight people. TargEDys’ first product, EnteroSatys® is based on the unique strain Hafnia alvei 4597 and its patented gut-brain axis mechanism of appetite regulation. EnteroSatys was named the probiotic of the year 2021 and Crescylia (IGFL) as the nutrition research project of the year! In May 2023, TargEDys is acquired by BIOCODEX group! It will strengthen BIOCODEX’s ambition to become the leader in Microbiota care. Show less

ATOPIUS HEALTH, is a spin-off of Monash University, a public research university based in Melbourne. The ambition of ATOPIUS HEALTH is to research and develop innovative pharmaceutical and nutritional solutions in the field of atopic diseases, in particular, eczema, asthma, and food allergies.

KYBORA is a global life science advisory firm committed to helping its clients achieve enduring success through M&A, licensing, and commercialization of pharmaceutical products and medical devices in markets around the world. Over the years, they have built unparalleled relationship networks that facilitate and accelerate business and corporate development projects. They have offices in the US, Mexico, Colombia, Brazil, Germany, Switzerland, Spain, and Saudi Arabia. In addition, they have… Show more KYBORA is a global life science advisory firm committed to helping its clients achieve enduring success through M&A, licensing, and commercialization of pharmaceutical products and medical devices in markets around the world. Over the years, they have built unparalleled relationship networks that facilitate and accelerate business and corporate development projects. They have offices in the US, Mexico, Colombia, Brazil, Germany, Switzerland, Spain, and Saudi Arabia. In addition, they have established strong partnerships in India, China, and Argentina, giving them access to strategic and financial investors located all over the world. Show less

- Shepherd the integration of ACTELION into JANSSEN Pharmaceutical Companies in LatAm.- Lead the Regional Organization consisting of Operating Companies and Commercial Strategy Teams (Strategic Marketing, Market Research, Strategic Analytics, Health Economics and Pricing, Medical Affairs and Regulatory).- Develop, lead and execute the Regional Commercial and Brands Strategy for ACTELION in LatAm.- Ensure that Value Excellence is incorporated into all aspects of the Regional… Show more - Shepherd the integration of ACTELION into JANSSEN Pharmaceutical Companies in LatAm.- Lead the Regional Organization consisting of Operating Companies and Commercial Strategy Teams (Strategic Marketing, Market Research, Strategic Analytics, Health Economics and Pricing, Medical Affairs and Regulatory).- Develop, lead and execute the Regional Commercial and Brands Strategy for ACTELION in LatAm.- Ensure that Value Excellence is incorporated into all aspects of the Regional commercial strategy in accordance to product life cycle stages and provide thoughtful input to ensure optimised access, pricing, and reimbursement within the evolving healthcare landscapes.- Interact and engage with Early Development Commercial Input Lead to define new spaces and opportunities for ACTELION.- Act as a business ambassador for the company interacting with a multi-stakeholder portfolio across the region in order to increase company/ brand awareness and reputation. Show less

Mission: Transform emerging countries into key sustainable growth platform by making a rapid shift from traditional marketing and sales approaches to access-driven and patient-centered commercial organization in a more and more cost-conscious environment • Full business responsibility over the countries of the region:- from budget planning, consolidated P&L, to business follow up (sales/opex/organization),- from organic growth of Actelion product-portfolio to external business… Show more Mission: Transform emerging countries into key sustainable growth platform by making a rapid shift from traditional marketing and sales approaches to access-driven and patient-centered commercial organization in a more and more cost-conscious environment • Full business responsibility over the countries of the region:- from budget planning, consolidated P&L, to business follow up (sales/opex/organization),- from organic growth of Actelion product-portfolio to external business development project (Orphan drugs + Speciality area e.g Rx and Generic business)Results: • Since 2012, continuous overachievement of my annual regional targets (revenues and EBIT) • Successful market access and launch of Actelion flagship product OPSUMIT (PAH) in all key markets• Ensuring sales momentum with TRACLEER (PAH) and ZAVESCA (NP-C) after generics launch by driving market development with the implementation of patient-centered approach (patient support programmes with diagnostic support software supply)• Leading ACTELION geographical extension in new territories with the opening of new affiliates in Hungary (2011) and Israel (2015) + new Business Development partnerships (CIS, South Africa and LatAm) Show less

Mission: With the strategic acquisition of Royal Numico, acceleration of DANONE commitment to innovation in order to bring health through food to as many people as possibleResults: - Contribution to the Group’s growth by anticipating, influencing, interpreting and guiding the management of public, scientific and regulatory issues of nutrition and general food- Development and execution of a new strategy to protect DANONE "Health Brand" Patrimony:• Creation of a public… Show more Mission: With the strategic acquisition of Royal Numico, acceleration of DANONE commitment to innovation in order to bring health through food to as many people as possibleResults: - Contribution to the Group’s growth by anticipating, influencing, interpreting and guiding the management of public, scientific and regulatory issues of nutrition and general food- Development and execution of a new strategy to protect DANONE "Health Brand" Patrimony:• Creation of a public, scientific and regulatory affairs organization with a new governance scheme• Advocacy and lobbying for Health Food at the Authorities/Agencies level (EU, US, Japan and China) • Approval by the health Authorities/Agencies of functional claims sustaining innovation and growth Show less

2004 - 2007: General Director VenezuelaTurnover in 2006: 150 million € and 500 employees Mission: Succeed the merger between SANOFI-SYNTHÉLABO and AVENTIS (Sept. 04) and foster results following years of local underperformance of AVENTIS-PHARMAResults: • Financial target achieved in 2005 (€ 105 million sales and € 46 million EBIT)•“Intercontinental Performance Award” for the best affiliate vs Budget and Market in 2005• Rapid and efficient integration process: The merger… Show more 2004 - 2007: General Director VenezuelaTurnover in 2006: 150 million € and 500 employees Mission: Succeed the merger between SANOFI-SYNTHÉLABO and AVENTIS (Sept. 04) and foster results following years of local underperformance of AVENTIS-PHARMAResults: • Financial target achieved in 2005 (€ 105 million sales and € 46 million EBIT)•“Intercontinental Performance Award” for the best affiliate vs Budget and Market in 2005• Rapid and efficient integration process: The merger was fully operational within 6 months• Redefinition of the market-access, marketing and sales strategies (prescription and self-medication) • Portfolio management: Re-balance between Core and Base Business with no negative impact on P&L• Cooperation agreement with the Venezuelan ministry of health: “Access to Medicines Program”2003 - 2004: General Director BrazilTurnover in 2004: 100 million € and 750 employees Mission: Regain market share following years of local underperformance of SANOFI-SYNTHÉLABO and the team demotivation due to repetitive top-management changes and sales force reorganizationResults: • Financial target achieved in 2004 outperforming the market (first time ever since 2000) • Improvement of the productivity level of the industrial plant by winning federal and regional tenders• Implementation of good management practices and training of the business support teams• “Sales force & marketing effectiveness” training: COMPASS & ETMS, ROI program, Coaching • Partnership with federal Health Authorities: Health Care Partnership program (MoH and FIOCRUZ) Show less

2001 - 2003: General Director Russia Turnover in 2002: 62 million € and 400 employeesMission: Outperformance of our competitors in a high potential market, without external growthResults: • +50% turnover becoming the fastest growing subsidiary in the group across the globe!• Launching of products in cardiovascular disorders, diabetes and cancer with positive impact on P&L • Opening of a pharmaceutical plant in Moscow for Russia and CIS countries1998 - 2001:… Show more 2001 - 2003: General Director Russia Turnover in 2002: 62 million € and 400 employeesMission: Outperformance of our competitors in a high potential market, without external growthResults: • +50% turnover becoming the fastest growing subsidiary in the group across the globe!• Launching of products in cardiovascular disorders, diabetes and cancer with positive impact on P&L • Opening of a pharmaceutical plant in Moscow for Russia and CIS countries1998 - 2001: General Director Portugal Turnover in 2001: 59 million € and 220 employeesMission: Consolidation of the market share of the 3rd largest subsidiary of SERVIERResults: +44% sales in 3 years. Co-marketing & toll-manufacturing with Azevedos and Ferraz Lynce1995 - 1998: General Director TurkeyTurnover in 1998: 50 million € and 270 employeesMission: Development of the Top SERVIER subsidiary in Asia, a highly competitive marketResults: +95% sales in 3 years; Toll-manufacturing with Turkish group Abdi Ibrahim1994 - 1995: General Director India Turnover in 1995: 10 million € and 200 employeesMission: Increase of turnover despite main brand affected by the launch of generics Results: +20% sales in 1 year. Licensing contract (generics) with local Indian companies Show less

Results: Implementation of WW innovative strategies to drive sales growth of the Neurosciences and Metabolism portfolio (Parkinson and depression, diabetes and obesity)

Creation of the West coast branch in Los Angeles in January 1988. Opening of the West coast affiliate with 20 employees in April 1989 - Production, distribution and promotion